removed Category:Cannabinoids using HotCat |
Accuracy (but still needs citation) Tag: Visual edit |
||
| Line 38: | Line 38: | ||
'''JWH-133''' is a potent selective [[Cannabinoid receptor type 2|CB<sub>2</sub> receptor]] agonist with a [[Dissociation constant|Ki]] of 3.4nM and selectivity of around 200x for CB<sub>2</sub> over [[Cannabinoid receptor type 1|CB<sub>1</sub>]] receptors. It was discovered by and named after, [[John W. Huffman]]. |
'''JWH-133''' is a potent selective [[Cannabinoid receptor type 2|CB<sub>2</sub> receptor]] agonist with a [[Dissociation constant|Ki]] of 3.4nM and selectivity of around 200x for CB<sub>2</sub> over [[Cannabinoid receptor type 1|CB<sub>1</sub>]] receptors. It was discovered by and named after, [[John W. Huffman]]. |
||
JWH-133, alongside [[WIN 55,212-2]] and [[HU-210]], is responsible for preventing the inflammation caused by [[Amyloid beta]] proteins involved in [[Alzheimer's Disease]], in addition to preventing cognitive impairment and loss of neuronal markers {{citation needed|date=October 2014}} |
JWH-133, alongside [[WIN 55,212-2]] and [[HU-210]], is responsible for preventing the inflammation caused by [[Amyloid beta]] proteins involved in [[Alzheimer's Disease]], in addition to preventing cognitive impairment and loss of neuronal markers .{{citation needed|date=October 2014}} This anti-inflammatory action is induced through agonist action at the CB<sub>2</sub> receptor, which prevents [[microglia]]l activation that elicits the inflammation. Additionally, cannabinoids at this receptor completely abolish [[neurotoxicity]] related to [[microglia]] activation in rat models.{{Citation needed|reason=This is a pretty serious claim, and lacks a citation to support that itself. Also, 'completely abolish' doesn't fit the rhetoric I'd expect from an expert in the field, making me skeptical about its accuracy.|date=June 2018}} |
||
It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in [[Madrid]].<ref>http://www.enewspf.com/index.php/latest-news/health-and-fitness/18029-marijuana-compound-halts-breast-cancer-tumor-growth-</ref> |
It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in [[Madrid]].<ref>http://www.enewspf.com/index.php/latest-news/health-and-fitness/18029-marijuana-compound-halts-breast-cancer-tumor-growth-</ref> |
||
Revision as of 16:23, 22 December 2019
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H32O |
| Molar mass | 312.489 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
JWH-133 is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman.
JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers .[citation needed] This anti-inflammatory action is induced through agonist action at the CB2 receptor, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids at this receptor completely abolish neurotoxicity related to microglia activation in rat models.[citation needed]
It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid.[1]
Legal Status
The substance commonly referred to as "JWH-133" is not a scheduled substance in the U.S, except in Alabama.[2] Low abuse potential makes it less likely for regulation relative to its sister drugs such as JWH-018, as JWH-133 is selective for the non-psychoactive CB2 receptor and thus lacks significant psychoactive effects.[3]
References
- ^ http://www.enewspf.com/index.php/latest-news/health-and-fitness/18029-marijuana-compound-halts-breast-cancer-tumor-growth-
- ^ "Alabama Senate Bill 333 - Controlled substances, Schedule I, additional synthetic controlled substances and analogue substances included in, trafficking in controlled substance analogues, requisite weight increased, Secs. 13A-12-231, 20-2-23 am'd". March 2014. Retrieved 28 September 2015.
- ^ http://www.usdoj.gov/dea/pubs/scheduling.html
External links
- JNeurosci.org Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation Also has been shown to block grown of tumors. More clinical studies and trials are needed.